+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Toll-like-receptor-agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-like-receptor-agonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-33 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-33 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Fc-Gamma Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Fc-Gamma Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
H 4 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

H 4 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
H 3 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

H 3 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
H 2 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

H 2 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Caspases Activators - Pipeline Insight, 2024 - Product Thumbnail Image

Caspases Activators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
HIV Attachment Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

HIV Attachment Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Autophagy modulators - Pipeline Insight, 2024 - Product Thumbnail Image

Autophagy modulators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Interleukin 1 beta inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin 1 beta inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Complement C5 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Complement C5 inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more